Lung is a major site of metastases for many primary cancers associated with poor outcomes. Enriching anti-tumorally active substances in the tumormicroenviroment is a very promising but challenging strategy for next generation cancer immunotherapy.

TRON scientist ‌Ayline Kübler has been chosen for a short talk at the upcoming 22nd CIMT Annual Meeting starting on May 12th, 2025.

Her talk entitled “Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune responses in MHC-I proficient and deficient lung metastases models” will address the use of cationic RNA-lipoplexes (LPX) that - upon intravenous injection - are targeting lung and tumor tissue in lung for delivery of mRNA-encoded cytokines.

Antitumoral efficacy is accompanied by increased NK and T cell activation and effector function as well as reduced Treg numbers and reduced Treg activation in lung as shown by flow cytometry and single cell RNA sequencing. Applying primary human tumor culture, immune cell activation and effector functions can be well reproduced upon treatment of patient-derived samples demonstrating the translational potential of this therapy. Collectively, she will provide a novel organ-directed approach for modulation of the innate as well as adaptive immune response for the treatment of lung metastases.

More information about CIMT: Speakers & Program